Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCENT
NCT04765644Phase 4Completed
- Sponsor
- Imperial College London
- Start
- Jun 2021
- Primary completion
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands, Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of celecoxib, arginine in endothelial dysfunction, sponsored by Imperial College London. Started Jun 2021; status: completed.
02
Drugs
celecoxibarginine
03
Conditions
endothelial dysfunction
Beyond the preview
Go deeper on NCT04765644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04765644.